Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)

被引：0
|
作者：
Leal, T. [1 ]
Wakelee, H. [2 ]
Reckamp, K. L. [3 ]
Chiappori, A. [4 ]
Oxnard, G. R. [5 ]
Waqar, S. N. [6 ]
Patel, S. P. [7 ]
Blumenschein, G. R. [8 ]
Neal, J. W. [2 ]
Harrow, K. [9 ]
Holzhausen, A. [9 ]
Selvaggi, G. [9 ]
Zhou, J. [9 ]
Horn, L. [10 ]
机构：
[1] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[2] Stanford Univ & Canc Inst, Stanford, CA USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Xcovery Holdings Inc, Palm Beach Gardens, FL USA
[10] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期
关键词：
ALK; NSCLC; ensartinib; CNS;
D O I：
10.1016/j.jtho.2019.09.131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD2.04
引用
收藏
页码：S1171 / S1172
页数：2
相关论文
共 50 条
  • [1] Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
    Wakelee, H.
    Reckamp, K.
    Leal, T.
    Chiappori, A.
    Waqar, S.
    Zeman, K.
    Neal, J.
    Liang, C.
    Harrow, K.
    Holzhausen, A.
    Zhou, J.
    Selvaggi, G.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S566 - S566
  • [2] Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
    Leal, T.
    Wakelee, H.
    Reckamp, K.
    Waqar, S.
    Patel, S.
    Blumenschein, G.
    Neal, J.
    Harrow, K.
    Holzhausen, A.
    Liang, C.
    Dukart, G.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S156 - S156
  • [3] Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC)
    Wakelee, H.
    Reckamp, K. L.
    Leal, T. A.
    Patel, S. P.
    Blumenschein, G.
    Shum, E.
    Nieva, J.
    Oxnard, G.
    Sanborn, R. E.
    Waqar, S.
    Zeman, K.
    Dukart, G.
    Harrow, K.
    Liang, C.
    Holzhausen, A.
    Horn, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients
    Horn, L.
    Wu, Y-L.
    Reck, M.
    Liang, C.
    Tan, F.
    Harrow, K.
    Oertel, V.
    Dukart, G.
    Mok, T. S. K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S116 - S116
  • [5] EXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
    Horn, L.
    Wu, Y-L.
    Reck, M.
    Liang, C.
    Tan, F.
    Harrow, K.
    Oertel, V.
    Dukart, G.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients
    Horn, Leora
    Wu, Yi-Long
    Reck, Martin
    Wakelee, Heather A.
    Liang, Chris
    Tan, Fenlai
    Harrow, Kimberly
    Oertel, Vance
    Dukart, Gary
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
    Horn, Leora
    Wu, Yi-Long
    Reck, Martin
    Liang, Chris
    Tan, Fenlai
    Harrow, Kimberly
    Oertel, Vance
    Dukart, Gary
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
    Imase, R.
    Endo, S.
    Sasahara, Y.
    Shinmura, T.
    Ozawa, T.
    Majima, H.
    Hara, T.
    Shimada, H.
    Yamauchi, S.
    Sakakibara, Y.
    Kobayashi, A.
    Yamazaki, K.
    Jin, Y.
    Yamanaka, K.
    Matsubara, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
  • [9] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Rosell, R.
    Gettinger, S. N.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114
  • [10] Post-Ensartinib Outcomes in Refractory Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
    Kim, H.
    Vu, P.
    Harrow, K.
    Liang, C.
    Selvaggi, G.
    Weihe, E.
    Mitchell, W.
    Bazhenova, L.
    Patel, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S577 - S578
12345